Anti-Inflammatory Tripeptide
Derived from alpha-MSH for inflammation support
KPV is a naturally occurring tripeptide fragment of alpha-melanocyte stimulating hormone (α-MSH) that powerfully modulates inflammatory responses throughout the body. By targeting key inflammatory pathways, KPV supports tissue healing, reduces chronic inflammation, and promotes gut health through its unique anti-inflammatory and antimicrobial properties.
10mg
Therapeutic Dosage
SC/IM
Administration
1-2x
Daily Dosing
4-8
Week Cycles
Available Dosing
Physician-prescribed anti-inflammatory therapy with comprehensive medical oversight and personalized dosing strategies.
Standard therapeutic dosage
Ideal For
Individuals managing chronic inflammatory conditions, inflammatory bowel disease, autoimmune conditions, skin inflammation, or seeking enhanced gut healing and mucosal repair.
The Science
KPV is a tripeptide consisting of three amino acids (lysine-proline-valine) naturally derived from alpha-melanocyte stimulating hormone (α-MSH), a critical immune-regulating peptide in the body. This small but powerful peptide plays a vital role in controlling inflammation by modulating key inflammatory pathways and inhibiting pro-inflammatory signaling cascades.
Unlike conventional anti-inflammatory drugs that suppress the entire immune system, KPV works intelligently by targeting specific inflammatory mediators. It inhibits pro-inflammatory cytokines while preserving beneficial immune responses, making it particularly effective for chronic inflammatory conditions where targeted inflammation control is essential.
Research has demonstrated KPV’s remarkable efficacy in supporting gut health, particularly in inflammatory bowel conditions such as ulcerative colitis and Crohn’s disease. The peptide exhibits both anti-inflammatory and antimicrobial properties, helping to restore intestinal barrier function, reduce mucosal inflammation, and promote healing of damaged gut tissue. Additionally, KPV has shown promise in managing skin inflammation, wound healing, and systemic inflammatory conditions by modulating immune responses at the cellular level.
Book a Consultation
How It Works
KPV reduces inflammation through multiple pathways that target pro-inflammatory signaling while supporting tissue healing and immune balance.
Directly inhibits nuclear factor kappa B (NF-κB), a master regulator of inflammatory gene expression, preventing production of pro-inflammatory cytokines like TNF-α and IL-6.
Exhibits broad-spectrum antimicrobial properties against pathogenic bacteria and biofilms, helping to rebalance gut microbiota and reduce inflammatory triggers from dysbiosis.
Promotes intestinal barrier integrity and mucosal tissue repair by reducing inflammation at the gut lining, supporting tight junction function and healing damaged epithelial cells.
Clinical Benefits
Clinically studied for reducing inflammation in ulcerative colitis and Crohn’s disease, helping to calm inflamed intestinal tissue and support remission.
Promotes intestinal barrier function by supporting tight junction integrity, reducing intestinal permeability (“leaky gut”), and enhancing mucosal defense mechanisms.
Modulates inflammatory cytokines throughout the body, helping to reduce chronic low-grade inflammation associated with metabolic disorders and aging.
Exhibits natural antimicrobial activity against pathogenic bacteria, biofilms, and harmful microorganisms, supporting a healthier gut microbiome balance.
Supports dermatological healing by reducing skin inflammation, promoting tissue repair, and addressing inflammatory skin conditions like eczema and psoriasis.
Helps regulate overactive immune responses in autoimmune conditions by balancing inflammatory pathways without broadly suppressing immune function.
Your Journey
Our medical team guides you through every step—from initial consultation to ongoing optimization.
Comprehensive evaluation of inflammatory conditions, gut health concerns, and treatment objectives.
Complete inflammatory markers, gut health testing, and baseline labs to assess condition severity and guide protocol design.
Receive personalized KPV dosing regimen based on your inflammatory profile, symptoms, and therapeutic goals.
Regular follow-ups with symptom tracking, inflammatory marker testing, and protocol adjustments for optimal inflammation control.
Safety & Candidacy
KPV has demonstrated an excellent safety profile in clinical research and therapeutic use. Our medical team evaluates each patient individually to ensure appropriate candidacy and optimal dosing strategies.
20+
Years of research demonstrating safety and anti-inflammatory efficacy
95%+
Patient tolerability rate with excellent safety profile
Questions
KPV works by inhibiting nuclear factor kappa B (NF-κB), a master regulator of inflammatory gene expression. By blocking NF-κB activation, KPV prevents the production of pro-inflammatory cytokines like TNF-alpha, IL-6, and IL-1β. This targeted approach reduces inflammation at the source without broadly suppressing the immune system. KPV also exhibits antimicrobial properties that help address inflammatory triggers from pathogenic bacteria, particularly in the gut.
KPV has been clinically studied for inflammatory bowel diseases (ulcerative colitis, Crohn’s disease), leaky gut syndrome, chronic inflammatory conditions, autoimmune disorders, skin inflammation (eczema, psoriasis), and wound healing. It’s particularly effective for gut-related inflammation due to its direct effects on intestinal barrier function and mucosal healing. Your BHRC physician will assess whether KPV is appropriate for your specific inflammatory condition.
KPV is administered via subcutaneous or intramuscular injection, typically at doses ranging from 200-500mcg per injection. Most protocols involve 1-2 daily injections depending on the severity of inflammation and individual response. Some patients may use KPV in cycles of 4-8 weeks, while others with chronic conditions may benefit from longer-term use. Your physician will design a personalized dosing protocol based on your specific needs and inflammatory markers.
Response times vary based on the condition being treated and individual factors. Some patients report reduced inflammatory symptoms within 1-2 weeks of consistent use. For gut-related conditions, noticeable improvements in digestive symptoms, bowel regularity, and abdominal discomfort often occur within 2-4 weeks. Measurable changes in inflammatory markers typically appear within 4-6 weeks. Long-term benefits, including sustained inflammation reduction and tissue healing, develop over 8-12 weeks of therapy.
KPV has an excellent safety profile with minimal reported side effects. Occasional mild injection site reactions (redness, tenderness) may occur. Unlike systemic immunosuppressants, KPV does not broadly suppress immune function. However, individuals with active infections should consult with their physician before starting therapy. Comprehensive medical evaluation ensures safe and appropriate use. There are no known significant drug interactions, but full disclosure of medications is essential during your consultation.
Yes, KPV can be safely combined with other peptide therapies, gut healing protocols, and anti-inflammatory interventions. Many patients use KPV alongside BPC-157 for enhanced gut healing, with other immune-modulating peptides, or as part of comprehensive inflammatory management programs. KPV is generally compatible with conventional medications, but your BHRC physician will review all current treatments to design an integrated protocol optimized for your specific condition.
KPV peptide therapy is typically not covered by insurance as it’s considered preventive and regenerative medicine. BHRC offers transparent pricing and flexible payment options to make this innovative therapy accessible. Many patients find the investment worthwhile given the significant impact on inflammatory control and overall quality of life. Our team can provide detailed cost information and discuss payment plans during your consultation.
Get Started
Schedule a consultation with our medical team to learn if KPV peptide therapy is right for your wellness journey.
"*" indicates required fields
Or call us directly: +1 213-325-3373
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. KPV is provided for anti-inflammatory support and wellness purposes under physician supervision. Individual results may vary. A consultation with our medical team and baseline laboratory testing are required to determine if this therapy is appropriate for you.
KPV is a short tripeptide fragment (lysine–proline–valine) derived from the alpha-MSH hormone, studied for its anti-inflammatory signalling. It is used most often for gut-related and inflammatory skin concerns. Because those concerns frequently have serious underlying causes, the first job of a KPV consultation is ruling out what should not be treated with a peptide.
KPV is generally well tolerated, which sometimes leads patients to treat it casually. The risk is not usually the peptide itself — it is spending months on it while an undiagnosed condition progresses untreated. For the full technical breakdown — dosing ranges, reconstitution math, syringe calculations and cycle structures — see our BPC-157 dosage guide.
Book a KPV ConsultationResponse varies between individuals, and the timeline below reflects what patients on a supervised protocol commonly report rather than a guaranteed outcome. Your provider will set expectations specific to your labs, history and goals.
| Timeframe | What patients typically report |
|---|---|
| Weeks 1–2 | Typically little perceptible change. Some patients with GI-focused protocols report early changes in bloating or stool consistency; this is variable and not predictive of the final result. |
| Weeks 2–4 | The window in which most patients who respond first notice something — commonly reduced GI discomfort, or reduced redness and irritation in dermatologic cases. |
| Weeks 4–6 | Changes tend to consolidate. This is usually when photographic comparison or symptom scoring shows a difference that is visible to someone other than you. |
| Weeks 6–8 | Formal reassessment. Inflammatory markers are re-checked where they were part of the baseline, and the decision is made to continue, taper or stop. |
| After the course | Many patients do not continue indefinitely. KPV is commonly used in defined courses around symptomatic periods rather than as a permanent daily therapy. |
KPV is often researched alongside other repair and anti-inflammatory peptides, and patients frequently arrive having read that they are interchangeable. They are not — they act through different mechanisms and suit different targets.
| Option | Primary use | Administration | Best suited to |
|---|---|---|---|
| KPV | Anti-inflammatory signalling; gut and skin focus | Oral capsule or subcutaneous | Inflammatory GI and dermatologic concerns |
| BPC-157 | Tissue repair, gut lining, musculoskeletal recovery | Oral or subcutaneous | Injury recovery and gut-lining repair |
| TB-500 | Systemic tissue repair and mobility | Subcutaneous | Musculoskeletal recovery, often stacked with BPC-157 |
| GHK-Cu | Skin remodelling, collagen signalling | Subcutaneous or topical | Skin quality, healing and cosmetic concerns |
| Thymosin Alpha-1 | Immune modulation | Subcutaneous | Immune support under specific clinical circumstances |
KPV and BPC-157 are the pair most often confused, and they are genuinely complementary in some protocols — KPV weighted toward inflammatory signalling, BPC-157 toward repair. Combining them is a clinical decision with a rationale, not a default.
Inflammatory conditions fluctuate on their own, which makes them unusually easy to misread. Without a documented baseline it is very difficult to distinguish a real treatment effect from a symptom cycle that would have improved anyway.
At reassessment the honest question is whether anything measurably changed. If not, extending the course or raising the dose is rarely the right answer, and your provider will discuss alternatives with you.
It depends on the target. Oral KPV acts locally along the GI tract and is generally selected when the gut lining itself is the concern. Subcutaneous administration is generally selected for systemic or dermatologic targets. This is a clinical decision made in consultation — the two are not interchangeable, and choosing the wrong route is a common reason protocols underperform.
Yes. BHRC prescribes and dispenses KPV under provider supervision after a consultation. We do not supply it as an unsupervised product. Peptides sold online under ‘research use only’ labelling fall outside that framework and carry genuine sourcing, purity and legal risk.
Cost varies with formulation, course length and whether any lab work is required. Pricing is reviewed transparently during your consultation before anything is prescribed. Peptide therapy is generally not covered by insurance.
No. KPV is not a treatment for diagnosed inflammatory bowel disease and must not replace prescribed therapy. Some patients use it as a supervised adjunct alongside their gastroenterology care, coordinated with their treating specialist. If you have IBD, that coordination is not optional.
No. KPV is not an FDA-approved drug. It is accessed through compounding pharmacies and used off-label under provider supervision. Human research is limited relative to established medications, which is exactly why supervision and structured reassessment matter.
They work through different mechanisms. KPV is studied primarily for anti-inflammatory signalling; BPC-157 is studied primarily for tissue repair. They overlap in gut applications, which is why they are often confused and sometimes used together — but combining them should follow a clinical rationale rather than a forum protocol.
Patients who respond most often report changes between weeks two and four, with consolidation by weeks four to six. Formal reassessment happens at four to eight weeks. If nothing has shifted by that point, continuing is unlikely to change the outcome.
KPV is generally well tolerated. The most commonly reported issues are mild GI upset with oral formulations and injection-site reactions — redness or tenderness — with subcutaneous use. Anything persistent, severe or unexpected should be reported to your provider promptly.
BHRC offers physician-supervised peptide therapy across its locations, including West Hollywood, West Los Angeles, Valencia, Paradise Valley and Summerlin. Your consultation determines candidacy, route and protocol, with follow-up handled through your treating location.
Yes, and it commonly is — most often with BPC-157 for gut protocols. Each addition increases both cost and complexity, so every element should have a stated reason. Stacking decisions are made in consultation after reviewing your history and current medications.
KPV is most often run as part of a broader repair or anti-inflammatory protocol. These are the pages worth reading next.
The literature below is peer-reviewed background on KPV and the mechanisms discussed on this page. It is provided so you can read the primary sources yourself. It is not evidence of any particular outcome at BHRC, and much of it is preclinical — animal or cell-culture work that has not been replicated in humans. Your provider will discuss what the evidence does and does not support for your situation.
Dosage & Protocol Library
KPV is most often run alongside tissue-repair and recovery peptides. These guides cover exact dosing, reconstitution and cycling for the protocols we use most.
